Envigo Appoints Patricia Henahan As New Chief Financial Officer
Huntingdon (London) 9 June 2016: Envigo announced today that it has appointed Patricia Henahan to the position of Chief Financial Officer.
Ms. Henahan has extensive financial experience in the life sciences sector, including leadership roles at Eli Lilly, AstraZeneca, MedImmune and Hospira. She has strong expertise in financial analysis, strategic planning, R&D and operations, with a history of driving continuous improvement through the teams she has led.
"I am delighted that Pat has decided to join the team at Envigo," said Brian Cass, Chief Executive Officer. "Her background in pharmaceuticals and experience across the R&D process will bring valuable insight to our strategic planning as we continue to position Envigo as a leading provider of contract services and research models globally."
Prior to joining Envigo, Ms Henahan was Vice President of Finance for Hospira’s $3 billion US pharmaceutical business and was a key member of the executive team delivering double digit profit growth during her time there. Previous to that she was Chief Financial Officer of the AstraZeneca Group company iPR Pharmaceuticals. Ms Henahan also served for 10 years as a US Army Captain in the Medical Corps.
Ms. Henahan holds an MBA from The Wharton School at the University of Pennsylvania, a bachelor's degree in Biology from the University of Notre Dame, and is a Six Sigma Black Belt.
About Envigo
Envigo provides essential research services, models and products for pharmaceutical, crop protection, and chemical companies as well as universities, governments, and other research organizations. Our business is founded on a dedication to customer service and the expertise and experience of our 3,800 people. With over 50 locations worldwide, Envigo is committed to helping customers realize the full potential of their research and products as we work together to build a healthier and safer world.
Read more at envigo.com
Ms. Henahan has extensive financial experience in the life sciences sector, including leadership roles at Eli Lilly, AstraZeneca, MedImmune and Hospira. She has strong expertise in financial analysis, strategic planning, R&D and operations, with a history of driving continuous improvement through the teams she has led.
"I am delighted that Pat has decided to join the team at Envigo," said Brian Cass, Chief Executive Officer. "Her background in pharmaceuticals and experience across the R&D process will bring valuable insight to our strategic planning as we continue to position Envigo as a leading provider of contract services and research models globally."
Prior to joining Envigo, Ms Henahan was Vice President of Finance for Hospira’s $3 billion US pharmaceutical business and was a key member of the executive team delivering double digit profit growth during her time there. Previous to that she was Chief Financial Officer of the AstraZeneca Group company iPR Pharmaceuticals. Ms Henahan also served for 10 years as a US Army Captain in the Medical Corps.
Ms. Henahan holds an MBA from The Wharton School at the University of Pennsylvania, a bachelor's degree in Biology from the University of Notre Dame, and is a Six Sigma Black Belt.
About Envigo
Envigo provides essential research services, models and products for pharmaceutical, crop protection, and chemical companies as well as universities, governments, and other research organizations. Our business is founded on a dedication to customer service and the expertise and experience of our 3,800 people. With over 50 locations worldwide, Envigo is committed to helping customers realize the full potential of their research and products as we work together to build a healthier and safer world.
Read more at envigo.com